Your Article Summary
Active Biotechs rights issue substantially oversubscribed
Active Biotech, 06/16/09
Active Biotech's rights issue of approximately 256 million SEK, with pre-emptive rights for the company's shareholders, has been completed. A count has shown that the issue is oversubscribed by 71 percent; 99.4 percent of the shares offered were subscribed for with the support of subscription rights.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Position statement of the Portuguese Society of Nephrology on the clinical use of biotechnological drugs in renal patients
Portuguese Journal of Nephrology and Hypertension, 10/12/09
Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications
Pharmaceutical Technology, 10/14/09
Cardiac Cell Repair Therapy: A Clinical Perspective
Mayo Clinic Proceedings, 10/12/09
Article Search
Sponsor


See Latest Articles


